Individualizing IBD Care Beyond the Bowel, With David T. Rubin, MD David Rubin, MD

Published Date: 15 Oct 2026

David T. Rubin, MD, on the questions, screening tools, and system barriers standing between IBD care and the whole patient.

Read Full News

Latest News

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.

FIT Misses More CRCs in Women; Could Sex-Specific Thresholds Help?

FIT Misses More CRCs in Women; Could Sex-Specific Thresholds Help?

Long-Term Risankizumab Data Show Durable Crohn’s, Fistula Outcomes

Long-Term Risankizumab Data Show Durable Crohn’s, Fistula Outcomes

Optimizing IBD Treatment and Sequencing, With Jordan Axelrad, MD, MPH Jordan Axelrad, MD, MPH

Jordan Axelrad, MD, MPH, discusses first-line IBD therapy selection, sequencing after failure, treat-to-target monitoring, and evaluating new agents

Todays Updates

NeurologyLive® Brain Games: October 11, 2026 Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is recent therapeutic advances in MS!

This Week on NeurologyLive® — October 12, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Individualizing Advanced Therapies in Parkinson Disease: Hubert Fernandez, MD Hubert Fernandez, MD, Louie Pasculli

The director of the Center for Neurological Restoration at Cleveland Clinic discusses when to transition beyond oral medication and considerations for selecting device-aided therapies in PD.

What Comprehensive Disease Control Means for IBD, With David Rubin, MD David Rubin, MD

A gastroenterologist explains why treating bowel inflammation alone isn't enough to call inflammatory bowel disease "controlled."

How Candida Moves From Mouth to Gut in IBD, With Iliyan D. Iliev, PhD Iliyan D. Iliev, PhD

Weill Cornell investigator Iliyan D. Iliev, PhD, explains why fluconazole, not nystatin, cleared gut Candida in IBD.

LIBERTY: Prior Anti-Drug Antibodies Did Not Blunt SC Infliximab After Drug Holiday

LIBERTY: Prior Anti-Drug Antibodies Did Not Blunt SC Infliximab After Drug Holiday

Mirikizumab Shows Early Efficacy in Pediatric UC in SHINE-2 Trial

Mirikizumab Shows Early Efficacy in Pediatric UC in SHINE-2 Trial

Todays Updates

NeurologyLive® Brain Games: October 11, 2026 Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is recent therapeutic advances in MS!

This Week on NeurologyLive® — October 12, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Individualizing Advanced Therapies in Parkinson Disease: Hubert Fernandez, MD Hubert Fernandez, MD, Louie Pasculli

The director of the Center for Neurological Restoration at Cleveland Clinic discusses when to transition beyond oral medication and considerations for selecting device-aided therapies in PD.

What Comprehensive Disease Control Means for IBD, With David Rubin, MD David Rubin, MD

A gastroenterologist explains why treating bowel inflammation alone isn't enough to call inflammatory bowel disease "controlled."

How Candida Moves From Mouth to Gut in IBD, With Iliyan D. Iliev, PhD Iliyan D. Iliev, PhD

Weill Cornell investigator Iliyan D. Iliev, PhD, explains why fluconazole, not nystatin, cleared gut Candida in IBD.

LIBERTY: Prior Anti-Drug Antibodies Did Not Blunt SC Infliximab After Drug Holiday

LIBERTY: Prior Anti-Drug Antibodies Did Not Blunt SC Infliximab After Drug Holiday

Mirikizumab Shows Early Efficacy in Pediatric UC in SHINE-2 Trial

Mirikizumab Shows Early Efficacy in Pediatric UC in SHINE-2 Trial

Latest News

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.

Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.

FIT Misses More CRCs in Women; Could Sex-Specific Thresholds Help?

Long-Term Risankizumab Data Show Durable Crohn’s, Fistula Outcomes

Jordan Axelrad, MD, MPH, discusses first-line IBD therapy selection, sequencing after failure, treat-to-target monitoring, and evaluating new agents

News All Time

Abdominal Pain and Bloating: When to Consider HAE, MCAS, and EGIDs Brian Lacy, MD, PhD

Gastroenterologist Brian Lacy, MD, PhD, discusses how to differentiate HAE, MCAS, and eosinophilic GI disorders in patients with unexplained abdominal pain and bloating.

When Abdominal Pain Is Actually a Food Allergy: A GI Workup Brian Lacy, MD, PhD

Brian Lacy, MD, PhD, of Mayo Clinic discussed the stepwise approach to diagnosing non-IgE mediated food hypersensitivity at EAC 2026.

Tulisokibart Meets Phase 3 Endpoints in Ulcerative Colitis, First for Anti-TL1A Alex Hillenbrand

Tulisokibart became the first anti-TL1A therapy to achieve clinical remission in a phase 3 ulcerative colitis trial.

The HCPFive: Top News for Healthcare Providers from the Week of 06/21 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including phase 3 data, new clinical findings, and regulatory updates.

Obefazimod Delivers Week 44 Remission in Refractory UC Patients Alex Hillenbrand

Abivax’s ABTECT Part 2 showed Week 44 responses and safety consistency with obefazimod in refractory UC patients.

4 Gastroenterology Headlines You Missed in June 2026 Abigail Brooks, MA

Catch up on phase 3 data for tulisokibart and obefazimod, expert perspective on linaclotide's expanded FDA approval, and more.

Q2 2026 Recap: Gastroenterology News & Updates Abigail Brooks, MA

Catch up on Q2 GI headlines you may have missed, including an expanded FDA approval for linaclotide, a submission for risankizumab SC induction in Crohn’s, and more.

First Half 2026 Recap: Gastroenterology Alex Hillenbrand

Review the biggest gastroenterology news from the first half of 2026, including FDA updates, IBD advances, and key clinical trials.

SimpleScreen CRC Blood Test Meets Endpoints in Clinical Validation Study Abigail Brooks, MA

Freenome reported updated SimpleScreen CRC results showing 80.4% colorectal cancer sensitivity and 90% specificity.

How FDA Approval of SimpleScreen CRC Could Expand Colorectal Cancer Screening With Mark Fendrick, MD Mark Fendrick, MD

FDA approves Freenome's SimpleScreen CRC blood test for colorectal cancer screening in average-risk adults aged 45 years and older.

FDA Approves Freenome Blood Test for Colorectal Cancer Screening Alex Hillenbrand

FDA approves Freenome's SimpleScreen CRC blood test for colorectal cancer screening in average-risk adults aged ≥45 years.

TL1A Antibody Duvakitug Boosts Clinical Remission in UC, Response in CD Abigail Brooks, MA

Newly published phase 2b RELIEVE UCCD data show strong 14-week results for duvakitug in ulcerative colitis and Crohn disease.

"Forever Chemicals" Are in Cord Blood And Tied to Gut Inflammation in Kids Elizabeth Spencer, MD, MS

PFAS found in cord blood linked to childhood gut inflammation and IBD risk; Elizabeth Spencer, MD, explains what it means for patients.

Metabolic Dysfunction May Explain Sugar-Sweetened Beverage–Gastric Cancer Link, With Andrew Chan, MD, MPH Andrew Chan, MD, MPH

New findings link sugar-sweetened beverages, but not artificial sweeteners, to increased gastric cancer risk, possibly tied to metabolic dysfunction.

How a Physician With Crohn's Disease Approaches IBD Care Jordan Axelrad, MD, MPH

Jordan E. Axelrad, MD, MPH, on selecting first-line IBD therapy, treat-to-target monitoring, and how living with Crohn's shapes patient care.

ABTECT Part 2 Data: Obefazimod Sustains Remission in UC Remo Panaccione, MD, FRCPC

Remo Panaccione, MD, discusses ABTECT Part 2 data: about 37% of prior non-responders achieved remission, with no new safety signals.

Recommended News For You

Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

Overdosing on Chemotherapy: A Single Gene Test Could Prevent Hundreds of Deaths Annually.

SCOTUS Grapples With Multibillion-Dollar Lawsuits Over Roundup Cancer Claims

Major Shifts in Urothelial Cancer Care: Immunotherapy Redefines Standards

Resection for Early Liver Cancer Tied to Improved Survival.

The Cherenkov color image shows the possibility of improving the quality of radiation therapy.

Recommended Articles For You

Octreotide's Efficacy in Reducing Transfusion Requirements in Angiodysplasia Bleeding 

The Importance of Understanding Carboxyhemoglobin Levels in the Body: A Comprehensive Guide 

The Latest Research on Basal Cell Carcinoma: New Developments in Diagnosis and Cure  

Unlocking the Unknown: A Comprehensive Guide to Stage 4 Vulvar Cancer 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Taking Charge of Your Cancer Journey.

2.

Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.

3.

Can Fasting Around Chemo Improve Ovarian Cancer Outcomes?

4.

Does Telenursing Improve QOL in Breast Cancer?

5.

Sevabertinib Approved for First-Line Mutated NSCLC

1.

The Pros and Cons of Using Cyclophosphamide in Cancer Treatment 

2.

Predicting Incidental Prostate Cancer in BPH Surgery Patients

3.

Managing Acute Respiratory Failure in Hematological Malignancies

4.

AI in Genomics: Decoding the Human Genome for Cancer Treatment

5.

Modern Approaches to Detecting Residual Disease: Clinical Utility and Future Trends

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III

2.

Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II

3.

Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment

4.

Future of Hematology

5.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot